These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 9027276

  • 1. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial.
    Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, Berman J.
    Ann Intern Med; 1997 Feb 01; 126(3):232-6. PubMed ID: 9027276
    [Abstract] [Full Text] [Related]

  • 2. Allopurinol in the treatment of American cutaneous leishmaniasis.
    Martinez S, Marr JJ.
    N Engl J Med; 1992 Mar 12; 326(11):741-4. PubMed ID: 1738379
    [Abstract] [Full Text] [Related]

  • 3. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Esfandiarpour I, Alavi A.
    Int J Dermatol; 2002 Aug 12; 41(8):521-4. PubMed ID: 12207774
    [Abstract] [Full Text] [Related]

  • 4. Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.
    Momeni AZ, Reiszadae MR, Aminjavaheri M.
    Int J Dermatol; 2002 Jul 12; 41(7):441-3. PubMed ID: 12121563
    [Abstract] [Full Text] [Related]

  • 5. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study.
    Esfandiarpour I, Dabiri SH.
    Int J Dermatol; 2007 Aug 12; 46(8):848-52. PubMed ID: 17651170
    [Abstract] [Full Text] [Related]

  • 6. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.
    Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, Hooshmand B, Gorouhi F, Rashighi-Firoozabadi M, Dowlati Y.
    Arch Dermatol; 2006 Dec 12; 142(12):1575-9. PubMed ID: 17178983
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A.
    J Vector Borne Dis; 2008 Dec 12; 45(4):287-91. PubMed ID: 19248655
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of recurrent cutaneous Leishmaniasis.
    Momeni AZ, Aminjavaheri M.
    Int J Dermatol; 1995 Feb 12; 34(2):129-33. PubMed ID: 7737774
    [Abstract] [Full Text] [Related]

  • 15. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
    Soto J, Fuya P, Herrera R, Berman J.
    Clin Infect Dis; 1998 Jan 12; 26(1):56-8. PubMed ID: 9455509
    [Abstract] [Full Text] [Related]

  • 16. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years).
    Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C.
    Am J Trop Med Hyg; 1997 Dec 12; 57(6):651-5. PubMed ID: 9430521
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.